Dr Oliver Zolman
Dr Oliver Zolman
Longevity
Medical doctor and researcher specialising in longevity medicine, biological ageing, and translational therapeutics
Bioprofile
Dr Zolman is a medical doctor and researcher specialising in longevity medicine, biological ageing, and translational therapeutics. His work focuses on structured, multi-intervention approaches to ageing biology—integrating lifestyle optimisation, pharmacological strategies, and emerging therapies into cohesive, data-driven protocols designed to systematically improve human healthspan.
He is known for advancing a systems-based, biomarker-driven approach to ageing, where the body is treated as an interconnected network of measurable systems rather than isolated conditions. His work emphasises continuous measurement, iterative intervention, and protocol design aimed at optimising function across multiple biological pathways simultaneously.
Dr Zolman trained in regenerative and evidence-based medicine and has developed comprehensive frameworks to assess whole-body ageing. His work focuses on expanding the boundaries of what can be measured, tracked, and optimised in human biology through structured, data-driven approaches.
He is the architect of the “82 Organs Framework”, a system designed to assess and optimise function across the body at an organ-system level, and is connected to a global network of over 500 longevity-focused clinicians.
Dr Zolman has contributed to frontier initiatives in the field, including being recruited for involvement in the $101 million “XPRIZE Healthspan Prize”, and created “Project Blueprint” for Bryan Johnson (one of the most visible personalised longevity programmes globally) using his Longevity “Level 1-2-3” protocol, built on the principle that ageing can be quantified, monitored, and systematically improved through disciplined, multi-variable intervention.
His work and perspectives have been featured across major international media, including Netflix, BBC, Bloomberg, and The Times, reflecting the growing relevance of longevity science in mainstream healthcare and global discourse.
In his role as Executive in Residence, Dr Zolman will work closely with Brookstreet’s investment team to support the evaluation of longevity-focused opportunities, contribute domain expertise to due diligence and portfolio development, and help shape new strategies within this rapidly evolving sector.
